Literature DB >> 7428796

Decreased tyramine sensitivity after discontinuation of amitriptyline therapy. An index of pharmacodynamic half-life.

K Ghose.   

Abstract

A combined pharmacodynamic and pharmacokinetic approach was made to study the pharmacodynamic half-life (Pd1/2) of amitriptyline (AT). Six depressed patients were treated with 150 mg of amitriptyline as a single oral dose at night for six or more weeks. Decreased tyramine sensitivity (DTS), an index of this drug's pharmacological activity, was determined serially at various intervals after the last dose. Plasma concentrations of AT and nortriptyline (NT) were also estimated at above intervals. It was possible to detect DTS for 228-300 h after the last oral dose and the mean Pd1/2 of this decline of pharmacodynamic effect was observed to be 135 h. However, no measurable amount of AT or NT was present after 84 h and the mean elimination plasma half-life (t1/2) of AT and NT were 37.7 and 38.9 h, respectively. (In this study, pharmacokinetic parameters of NT were directly related with those of AT.) Prolonged pharmacodynamic effect of this drug after discontinuation should be borne in mind in order to avoid drug interactions and autonomic complications, especially after overdosage. Pd1/2, as assessed by DTS, correlated directly with the t1/2 (r = 0.91) and inversely with the plasma clearance rate (r = 0.60) of NT. DTS test can be used as an alternative technique to assess the biological activity of a drug which inhibits noradrenaline reuptake mechanism and/or blocks alpha-adrenoceptors at the peripheral neuronal sites, especially, where facilities to measure plasma concentrations of such drugs are limited.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7428796     DOI: 10.1007/bf00561583

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  CLINICAL TRIAL OF THE TREATMENT OF DEPRESSIVE ILLNESS. REPORT TO THE MEDICAL RESEARCH COUNCIL BY ITS CLINICAL PSYCHIATRY COMMITTEE.

Authors:  M THIERY
Journal:  Br Med J       Date:  1965-04-03

2.  Correlation of pupil reactivity to tyramine or hydroxyamphetamine and tyramine pressor responses in patients treated with amitriptyline or mianserin.

Authors:  K Ghose
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

Review 3.  Linear relationships between lipophilic character and biological activity of drugs.

Authors:  C Hansch; W J Dunn
Journal:  J Pharm Sci       Date:  1972-01       Impact factor: 3.534

4.  A specific gas-chromatographic method for the measurement of "steady-state" plasma levels of amitriptyline and nortriptyline in patients.

Authors:  R A Braithwaite; B Widdop
Journal:  Clin Chim Acta       Date:  1971-12       Impact factor: 3.786

5.  Protein binding nortriptyline and diphenylhydantoin in man.

Authors:  O Borgå; K M Lunde
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1970

6.  Assessment of Peripheral adrenergic activity and its interactions with drugs in man.

Authors:  K Ghose
Journal:  Eur J Clin Pharmacol       Date:  1980-04       Impact factor: 2.953

7.  Blood levels of drug at the equilibrium state after multiple dosing.

Authors:  J G Wagner; J I Northam; C D Alway; O S Carpenter
Journal:  Nature       Date:  1965-09-18       Impact factor: 49.962

8.  Antidepressant evaluation and the pharmacological actions of FG4963 in depressive patients.

Authors:  K Ghose; R Gupta; A Coppen; J Lund
Journal:  Eur J Pharmacol       Date:  1977-03-07       Impact factor: 4.432

9.  A clinical trial comparing sustained release amitryptyline (Saroten Retard) and conventional amitriptyline tablets (Saroten) in endogenously depressed patients with simultaneous determination of serum levels of amitryptyline and nortriptyline.

Authors:  P Liisberg; H Mose; A Amdisen; A Jørgensen; H E Petersen
Journal:  Acta Psychiatr Scand       Date:  1978-05       Impact factor: 6.392

10.  Autonomic actions and interactions of mianserin hydrochloride (Org. GB 94) and amitriptyline in patients with depressive illness.

Authors:  K Ghose; A Coppen; P Turner
Journal:  Psychopharmacology (Berl)       Date:  1976-09-17       Impact factor: 4.530

View more
  3 in total

1.  Complications of baclofen overdosage.

Authors:  K Ghose; K M Holmes; K Matthewson
Journal:  Postgrad Med J       Date:  1980-12       Impact factor: 2.401

2.  Inhibitors of serotonin and noradrenaline uptake in human plasma after withdrawal of zimelidine and clomipramine treatment.

Authors:  S B Ross; A Aberg-Wistedt
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

3.  Combined norepinephrine/serotonergic reuptake inhibition: effects on maternal behavior, aggression, and oxytocin in the rat.

Authors:  Elizabeth Thomas Cox; Thomas Merryfield Jarrett; Matthew Stephen McMurray; Kevin Greenhill; Vivian E Hofler; Sarah Kaye Williams; Paul Wayland Joyner; Christopher L Middleton; Cheryl H Walker; Josephine M Johns
Journal:  Front Psychiatry       Date:  2011-06-08       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.